Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin (Regulatory Post Marketing Commitment Plan)
N/A
N/A
Both
Breast Neoplasms
Trial Information
Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin (Regulatory Post Marketing Commitment Plan)
All the patients whom an investigator prescribes the first Exemestane (Aromasin) should be
registered.
Inclusion Criteria:
- Subjects with postmenopausal breast cancer (including ovariectomy etc.).
Exclusion Criteria:
- Patients cannot be evaluated.For example, not administered Exemestane (Aromasin).
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
Number of Participants With Factors Considered to Affect the Safety and/or Efficacy of Exemestane
Outcome Description:
Assessment of factors likely to affect the safety and/or efficacy: reason for Exemestane use (primary progressive breast cancer, relapsed breast cancer or postoperative adjuvant therapy)and past history (presence or absence of at least one disease).
Outcome Time Frame:
24 weeks
Safety Issue:
Yes
Principal Investigator
Pfizer CT.gov Call Center
Investigator Role:
Study Director
Investigator Affiliation:
Pfizer
Authority:
Japan: Pharmaceuticals and Medical Devices Agency
Study ID:
A5991078
NCT ID:
NCT00932165
Start Date:
December 2004
Completion Date:
November 2008
Related Keywords:
- Breast Neoplasms
- Breast Neoplasms
- Neoplasms
- Liver Diseases
Name | Location |
|---|
